Detalhe da pesquisa
1.
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Blood
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38620072
2.
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
Blood
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38620092
3.
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Blood
; 139(2): 177-187, 2022 01 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34758069
4.
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Blood
; 138(19): 1805-1816, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34086865
5.
Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group.
Ann Hematol
; 102(11): 3083-3090, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37358640
6.
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Haematologica
; 106(2): 543-554, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32107341
7.
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.
Br J Haematol
; 184(4): 558-569, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30506764
8.
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL).
Am J Hematol
; 94(9): 1002-1006, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31222797
9.
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
Am J Hematol
; 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38757754
10.
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
Am J Hematol
; 99(6): 1192-1195, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38578022
11.
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
Pharm Res
; 36(7): 93, 2019 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31044267
12.
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 19(9): 1215-1228, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30115596
13.
Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia.
Br J Haematol
; 183(5): 727-735, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30460980
14.
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
Blood
; 127(2): 208-15, 2016 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-26486789
15.
CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.
Future Oncol
; 14(6): 499-513, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29465308
16.
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
N Engl J Med
; 370(11): 997-1007, 2014 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24450857
17.
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
Haematologica
; 102(10): 1796-1805, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28751558
18.
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Lancet Oncol
; 17(2): 200-211, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26655421
19.
Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
Eur J Haematol
; 96(1): 9-18, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26332019
20.
Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.
Eur J Haematol
; 97(3): 253-60, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26643449